
| Biologics in systemic autoimmune diseases during COVID-19 pandemic #MMPMID33011932Annapureddy N; Nalleballe K; Onteddu SR; Sharma R; Sheng S; Kovvuru S; Siddamreddy S; Mandhadi RClin Rheumatol 2020[Dec]; 39 (12): 3529-3531 PMID33011932show ga
?|Adult[MESH]|Aged[MESH]|Arthritis, Juvenile/drug therapy/epidemiology[MESH]|Arthritis, Psoriatic/drug therapy/epidemiology[MESH]|Arthritis, Rheumatoid/drug therapy/epidemiology[MESH]|Autoimmune Diseases/*drug therapy/epidemiology[MESH]|Betacoronavirus[MESH]|Biological Products/*therapeutic use[MESH]|COVID-19[MESH]|Colitis, Ulcerative/drug therapy/epidemiology[MESH]|Coronavirus Infections/*epidemiology/mortality/therapy[MESH]|Critical Care/*statistics & numerical data[MESH]|Crohn Disease/drug therapy/epidemiology[MESH]|Female[MESH]|Hospitalization/*statistics & numerical data[MESH]|Humans[MESH]|Immunosuppressive Agents/*therapeutic use[MESH]|Intubation, Intratracheal/statistics & numerical data[MESH]|Male[MESH]|Middle Aged[MESH]|Mortality[MESH]|Pandemics[MESH]|Pneumonia, Viral/*epidemiology/mortality/therapy[MESH]|SARS-CoV-2[MESH]|Spondylitis, Ankylosing/drug therapy/epidemiology[MESH]
  
DeepDyve Pubget Overpricing | 
|